Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
I am pretty sure I understand the underpinnings and implications of the technology (due to my day job). Some of it is really straightforward. Here is a paragraph I wrote after the Stonechecker trials in 2017:
"Clinicians participating in the tests were unexpectedly enthusiastic about
StoneChecker's reporting of the basic stone parameters: position in the body, volume, and
shape. This automatically-provided, straightforward information allows the clinician to align
the lithotripsy equipment more accurately, making the treatment more effective and the
clinician's job much easier. These outputs from StoneChecker are much more
straightforward than the composite score which the software was designed to produce, and
are consequently a much easier sell. It seems likely that the software will be quickly adopted
by a majority of kidney stone treatment providers."
I really hate resorting to conspiracy theories, but the straight line in share price vs time looks extremely dodgy to me, I don't think it's likely that market forces would move the price in such a steady way over the last 5 days.
Personally it is interesting to read a variety of opinions.
I think it was me that frickd was having a pop at, though I didn't say hundreds of millions based on Stonechecker alone. What I wrote was:
"Back in 2017 I calculated a plausible market cap of £150M based on successful execution of the Stonechecker (kidney stone imaging) rollout alone:
"The cost of a single lithotripsy treatment is around £750 in India or the
Philipines. If we adopt this as an average global cost, assume a potential population with
access to treatment of 3 billion people, and assume that StoneChecker is licensed for use on
a single patient by StoneChecker Software Ltd for 0.1% of the cost of a single lithotripsy
treatment, this indicates an annual revenue stream of £18M. Software companies have
relatively fixed costs, so the overwhelming majority of this revenue should become net
income. If we assume a price-earnings ratio of 10, this implies a market cap around £150M
once StoneChecker is widely adopted."
I think if frickd disagrees with my conclusion frickd should point out which part of the reasoning above is wrong.
I am pretty sure hasiba's buy was real as I saw it on the reported trades.
DYOR obvs.
yes, it took me a few days to work out that there was nothing to worry about on Nov 17th because the selling to keep TB's share under 30% had already happened. But I did work it out eventually!
I just bought a few more at 10.71
I think £150M is undervaluing the IP by a considerable margin - factor of 3 or 4 at least. I think Stonechecker alone, if successfully deployed globally commands a market cap of £150M. I posted my reasoning supporting this a couple of times already recently.
still holding - have been for years.
I think the prospects are good, and am tempted to buy more.
Emotionally easier when in profit, but objectively the question is if you sell what will you do with the proceeds? Will the alternative be a better investment? Not in my view.
GLA
managed to get the £5k I had been looking to buy on friday at 13.00p in early trading today. Chuffed to have wrapped £10k of my IQAI holding in an ISA over the last few days.
"Fortunately" I have plenty of capital losses to offset against my remaining unwrapped IQAI... lol!
"Gadolinium-based contrast agents (GBCAs) are used over 10 million times worldwide each year in magnetic resonance imaging (MRI) scans to diagnose and characterize disease states affecting the central nervous system ...
In 2006 an association was established between GBCAs and a rare but devastating, and sometimes fatal, fibrosing disorder termed nephrogenic systemic fibrosis (NSF) in patients with impaired kidney function. ...
Deposition of Gd in the brain and other organs, e.g. bone, has been observed with all GBCAs regardless of kidney function ...
The FDA assigned a new class warning to all GBCAs advising physicians to carefully consider the retention characteristics of a GBCA before prescribing contrast enhanced examinations. ...
All intravenous contrast agents approved for use and that are commercially available contain Gd.
from Gale & Caravan 2018, "Gadolinium-free contrast agents for magnetic resonance imaging of the central nervous system" DOI: 10.1021/acschemneuro.8b00044 , https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994911/
sorry posted in the wrong thread earlier.
I think my average is about 4p. Difficult to work out exactly as did some selling and re-purchasing to wrap shares for tax purposes. I hold 0.75M shares.